Skip to main content

Market Overview

Why Turning Point's Stock Is Trading Higher Today


Turning Point Therapeutics (NASDAQ: TPTX) shares are trading higher on Wednesday.

Wells Fargo has maintained its Overweight rating on the stock and raised its price target from $62 to $76 per share.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies.

Turning Point Therapeutics shares were up 8.08% at $56.99 at time of publication on Wednesday. The stock has a 52-week high of $67.54 and a 52-week low of $29.47.

Related Links:

Volunteers Begin Testing Moderna Coronavirus Vaccine

Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus

Latest Ratings for TPTX

Feb 2021Canaccord GenuityMaintainsBuy
Jan 2021HC Wainwright & Co.MaintainsBuy
Dec 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for TPTX
View the Latest Analyst Ratings


Related Articles (TPTX)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Price Target Analyst Ratings

Latest Ratings

ONTFNeedhamInitiates Coverage On70.0
ONTFKeyBancInitiates Coverage On70.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at